Octreotide therapy of growth hormone excess in the McCune-Albright syndrome

S. I. Sherman, P. W. Ladenson

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


We report a patient with the McCune-Albright syndrome and growth hormone excess. Biochemical evaluation demonstrated characteristic changes typical of acromegaly, and an unusual pattern of delayed somatotropin response to hGHRH40, not previously described in this syndrome. Therapeutic trial of low-dose octreotide successfully reversed his growth hormone excess, whereas bromocriptine failed to reduce growth hormone levels. Previous reports of acromegaly and McCune-Albright syndrome are reviewed, and the unique features of this case discussed

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalJournal of endocrinological investigation
Issue number3
StatePublished - Mar 1992


  • McCune-Albright syndrome
  • acromegaly
  • octreotide

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Octreotide therapy of growth hormone excess in the McCune-Albright syndrome'. Together they form a unique fingerprint.

Cite this